Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1979 Feb 3;120(3):322-4, 329.

Cancer immunotherapy.

S P Richman, J U Gutterman, E M Hersh
PMCID: PMC1818999  PMID: 371776

Abstract

Important contributions that stimulated studies in cancer immunotherapy included: (1) the discovery of tumour-associated antigens; (2) the observation that infection with bacille Calmette-Guérin (BCG) in animals was protective against tumour challenge; and (3) the observation that immunodepression due either to malignant disease or to treatment of the disease, was, in some instances, related to prognosis. Immunotherapy trials with microbial agents have involved attempts to obtain a local effect by injecting the agent into the tumour or into the region of the tumour and to obtain a "systemic" effect distant from the site of injection. Trials with active specific immunotherapy involving tumour cells or tumour cell extracts have frequently involved the combination of these specific agents with a nonspecific adjuvant such as BCG. Recent studies with thymosin and levamisole in patients with lung cancer and other types of malignant disease have shown prolonged survival in the groups receiving immunotherapy.

Full text

PDF
322

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Band P. R., Jao-King C., Urtasun R. C., Haraphongse M. Phase I study of corynebacterium parvum in patients with solid tumors. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1139–1145. [PubMed] [Google Scholar]
  2. Bjornsson S., Takita H., Kuberka N., Preisler H., Catane H., Higby D., Henderson E. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer. Cancer Treat Rep. 1978 Apr;62(4):505–510. [PubMed] [Google Scholar]
  3. Bluming A. Z., Vogel C. L., Ziegler J. L., Mody N., Kamya G. Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann Intern Med. 1972 Mar;76(3):405–411. doi: 10.7326/0003-4819-76-3-405. [DOI] [PubMed] [Google Scholar]
  4. Currie G. A., McElwain T. J. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer. 1975 Feb;31(2):143–156. doi: 10.1038/bjc.1975.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eilber F. R., Morton D. L., Holmes E. C., Sparks F. C., Ramming K. P. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976 Jan 29;294(5):237–240. doi: 10.1056/NEJM197601292940501. [DOI] [PubMed] [Google Scholar]
  6. Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  7. Gutterman J. U., Mavligit G., Gottlieb J. A., Burgess M. A., McBride C. E., Einhorn L., Freireich E. J., Hersh E. M. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med. 1974 Sep 19;291(12):592–597. doi: 10.1056/NEJM197409192911202. [DOI] [PubMed] [Google Scholar]
  8. Hedley D. W., McElwain T. J., Currie G. A. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer. 1977 Oct;13(10):1169–1173. doi: 10.1016/0014-2964(77)90017-2. [DOI] [PubMed] [Google Scholar]
  9. Hersh E. M., Mavligit G. M., Gutterman J. U. Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient. Med Clin North Am. 1976 May;60(3):623–639. doi: 10.1016/s0025-7125(16)31902-2. [DOI] [PubMed] [Google Scholar]
  10. Hersh E. M., Whitecar J. P., Jr, McCredie K. B., Bodey G. P., Sr, Freireich E. J. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med. 1971 Nov;285(22):1211–1216. doi: 10.1056/NEJM197111252852201. [DOI] [PubMed] [Google Scholar]
  11. Israël L., Edelstein R., Depierre A., Dimitrov N. Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings. J Natl Cancer Inst. 1975 Jul;55(1):29–33. doi: 10.1093/jnci/55.1.29. [DOI] [PubMed] [Google Scholar]
  12. Kedar E., Nahas F., Unger E., Weiss D. W. In vitro induction of cell-mediated immunity to murine leukemia cells. III. Effect of methanol extraction residue fraction of BCG on the generation of cytotoxic lymphocytes against leukemia. J Natl Cancer Inst. 1978 May;60(5):1097–1106. doi: 10.1093/jnci/60.5.1097. [DOI] [PubMed] [Google Scholar]
  13. Klein E. Hypersensitivity reactions at tumor sites. Cancer Res. 1969 Dec;29(12):2351–2362. [PubMed] [Google Scholar]
  14. Levo Y., Rotter V., Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine. 1975 Jun 30;23(6):198–200. [PubMed] [Google Scholar]
  15. Mathé G., Pouillart P., Lapeyraque F. Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969 Dec;23(4):814–824. doi: 10.1038/bjc.1969.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Morales A., Eidinger D., Bruce A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180–183. doi: 10.1016/s0022-5347(17)58737-6. [DOI] [PubMed] [Google Scholar]
  17. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  18. OLD L. J., BENACERRAF B., CLARKE D. A., CARSWELL E. A., STOCKERT E. The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 1961 Oct;21:1281–1300. [PubMed] [Google Scholar]
  19. OLD L. J., CLARKE D. A., BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
  20. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  21. Schafer L. A., Goldstein A. L., Gutterman J. U., Hersh E. M. In vitro and in vivo studies with thymosin in cancer patients. Ann N Y Acad Sci. 1976;277(00):609–620. doi: 10.1111/j.1749-6632.1976.tb41733.x. [DOI] [PubMed] [Google Scholar]
  22. Silverstein M. J., DeKernion J., Morton D. L. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. JAMA. 1974 Aug 5;229(6):688–688. [PubMed] [Google Scholar]
  23. Webb H. E., Oaten S. W., Pike C. P. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum. Br Med J. 1978 Feb 11;1(6109):338–340. doi: 10.1136/bmj.1.6109.338. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES